Related references
Note: Only part of the references are listed.Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin
Biki Gupta et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2017)
Development of Bioactive PEGylated Nanostructured Platforms for Sequential Delivery of Doxorubicin and Imatinib to Overcome Drug Resistance in Metastatic Tumors
Biki Gupta et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles
Biki Gupta et al.
AAPS PHARMSCITECH (2016)
Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
Xue-Qin Yang et al.
BMC CANCER (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Modulation of Pharmacokinetic and Cytotoxicity Profile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers
Biki Gupta et al.
PHARMACEUTICAL RESEARCH (2015)
Lipid-coated polymeric nanoparticles for cancer drug delivery
Sangeetha Krishnamurthy et al.
BIOMATERIALS SCIENCE (2015)
Advances and Challenges of Liposome Assisted Drug Delivery
Lisa Sercombe et al.
FRONTIERS IN PHARMACOLOGY (2015)
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
J. L. Xu et al.
PLOS ONE (2015)
Chemotherapy for advanced non-small cell lung cancer in the elderly population
Fabio N. Santos et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?
Hisataka Kobayashi et al.
THERANOSTICS (2014)
Nanoparticles for Combination Drug Therapy
Liang Ma et al.
ACS NANO (2013)
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Anu Puri et al.
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
Linda Leung et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Bryan A. Faller et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Development and optimization of solid lipid nanoparticles of amikacin by central composite design
Jaleh Varshosaz et al.
JOURNAL OF LIPOSOME RESEARCH (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Nanoparticle-assisted combination therapies for effective cancer treatment
Che-Ming Jack Hu et al.
THERAPEUTIC DELIVERY (2010)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
Rogerio Lilenbaum et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Erlotinib in non-small cell lung cancer treatment: Current status and future development
Cesare Gridelli et al.
ONCOLOGIST (2007)
Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC -: a phase II trial
A. Babiak et al.
BRITISH JOURNAL OF CANCER (2007)
Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
Q Chu et al.
LUNG CANCER (2005)
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)
RC Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Paclitaxel for non-small cell lung cancer
S Ramalingam et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis
J Rejman et al.
BIOCHEMICAL JOURNAL (2004)
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel
YM Chen et al.
LUNG CANCER (2003)
Platinum drugs in the treatment of non-small-cell lung cancer
J Cosaert et al.
BRITISH JOURNAL OF CANCER (2002)
Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study
I Monnet et al.
ANNALS OF ONCOLOGY (2002)
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated
YM Chen et al.
ANNALS OF ONCOLOGY (2002)
Prognostic molecular markers in non-small cell lung cancer
J Niklinski et al.
LUNG CANCER (2001)
The role of mitomycin in the treatment of non small cell lung cancer: a systematic review with meta-analysis of the literature
JP Sculier et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
